February 16th 2024
The FDA has approved lifileucel, a tumor infiltrating lymphocyte therapy, for the treatment of advanced melanoma.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How Immunotherapies are Changing the Treatment of Melanoma
March 12th 2014Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Read More
AR Findings Highlight Detailed Tumor-Profiling Study
March 7th 2014A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Read More
MK-3475 to be Evaluated Across Wide Range of Cancers
February 7th 2014Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of MK-3475 across multiple tumor types. The agreements were signed through subsidiaries with Amgen Inc., Incyte Corporation, and Pfizer Inc.
Read More
The Changing Landscape of Immunotherapies for the Treatment of Melanoma
January 18th 2014Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, comments on the changing landscape of immunotherapies for the treatment of melanoma.
Watch
Trametinib-Dabrafenib Combination Approved for Advanced Melanoma
January 10th 2014The combination of the MEK inhibitor trametinib (Mekinist) and the BRAF inhibitor dabrafenib (Tafinlar) has received an accelerated approval from the FDA as a treatment for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.
Read More
Two BRAF Fusions Discovered in Some Pan-Negative Melanomas
December 21st 2013The discovery of two unique molecular targets known to speed skin-cancer growth has researchers excited that they might soon understand and develop genetic therapies geared toward some of medicine’s most untreatable melanomas.
Read More
The Challenges of Treating Metastatic Melanoma With BRAF Inhibitor Monotherapy
December 17th 2013Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.
Read More
The Difference Between Blocking PD-1 and PD-L1 in Melanoma
November 27th 2013Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.
Watch
A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanoma
November 21st 2013T-VEC, a novel oncolytic immunotherapy derived from the herpes simplex virus type 1, demonstrated a significant improvement in DRR, the primary endpoint in a pivotal phase III trial in patients with stage IIIB-IV melanoma.
Read More